Six-month safety and efficacy outcomes from the randomized-controlled arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial
Kidney International · 2025
DOI: 10.1016/j.kint.2025.01.006 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Kidney International, 2025. Verfasst von Mahmood K Razavi und 7 weiteren Autor:innen. Beteiligte Einrichtung: St. Joseph Heart and Vascular Center, Orange, California, USA. Electronic address: mrazavi@pacbell.net. Hauptthemen laut MEDLINE: Arteriovenous Shunt, Surgical, Renal Dialysis, Graft Occlusion, Vascular, Angioplasty, Balloon. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merit Medical Systems Inc.
Abstract (Originalsprache)
Stenosis within the arteriovenous fistula (AVF) of hemodialysis patients leads to vascular access dysfunction and inadequate hemodialysis. Percutaneous transluminal angioplasty (PTA) is the standard therapy for stenosis. However, rates of restenosis and loss of access patency remain high. Outcomes of a novel cell-impermeable endoprosthesis (CIE) have not been investigated in this setting. Therefore, our study was designed to address this as a prospective, international, multicenter pivotal trial (NCT04540302) with 245 patients with stenosis in their venous outflow circuit randomized to treatment: 122 receiving CIE and 123 receiving PTA across 43 international centers. Primary endpoints included target lesion primary patency (TLPP) at six months (freedom from clinically driven target lesion revascularization or target lesion thrombosis) and freedom from safety events through 30 days post-index procedure that affected the access circuit and resulted in reintervention, hospitalization, or death. Access circuit primary patency (ACPP) was evaluated as a secondary efficacy endpoint. Six-month TLPP and ACPP were significantly higher for the CIE cohort versus PTA (TLPP: 89.6% vs. 62.3%; ACPP: 72.2% vs. 57.0%). Thirty days post-index procedure, there was no statistically significant difference in the freedom from safety events for the CIE versus PTA (96.6 vs. 95.0%). No differences were observed in adverse events between either cohort. Our study shows that among patients with stenosis in their AVF, the CIE was superior to PTA with respect to six-month TLPP and ACPP with no observed difference in 30-day primary safety events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- St. Joseph Heart and Vascular Center, Orange, California, USA. Electronic address: mrazavi@pacbell.net.
- Texas Research Institute, PPG Health, Fort Worth, Texas, USA.
- Chicago Access Care, Westmont, Illinois, USA.
- North Carolina Nephrology, Raleigh, North Carolina, USA.
- University of Rio de Janeiro State, Rio de Janeiro, Rio de Janeiro, Brazil.
- University of North Carolina Kidney Center, Chapel Hill, North Carolina, USA; W.G. (Bill) Hefner Salisbury Department of Veterans Affairs Medical Center, Salisbury, North Carolina, USA.
Förderung
- Merit Medical Systems Inc
Zitieren
APA
Razavi, M. K., Balamuthusamy, S., Makris, A. N., Hoggard, J. G., Harduin, L. O., Roy-Chaudhury, P., Jones, R. G., & WAVE Trial Investigators (2025). Six-month safety and efficacy outcomes from the randomized-controlled arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial. Kidney International. https://doi.org/10.1016/j.kint.2025.01.006
Vancouver
Razavi MK, Balamuthusamy S, Makris AN, Hoggard JG, Harduin LO, Roy-Chaudhury P, et al. Six-month safety and efficacy outcomes from the randomized-controlled arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial. Kidney International. 2025. doi:10.1016/j.kint.2025.01.006
BibTeX
@article{Razavi2025,
author = {Razavi, Mahmood K and Balamuthusamy, Saravanan and Makris, Angelo N and Hoggard, Jeffrey G and Harduin, Leonardo O and Roy-Chaudhury, Prabir and Jones, Robert G and WAVE Trial Investigators, WAVE Trial Investigators},
title = {Six-month safety and efficacy outcomes from the randomized-controlled arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial},
journal = {Kidney International},
year = {2025},
doi = {10.1016/j.kint.2025.01.006}
}
EUVIMED